Acurx Pharmaceuticals, Inc. filed a Form 8-K on November 20, 2026, disclosing the unexpected passing of board member Thomas Harrison on November 18, 2026.

Key Highlights

  • Board member death disclosed: Thomas Harrison, a member of the Acurx Pharmaceuticals Board of Directors, unexpectedly passed away on November 18, 2026.
  • Board tenure: According to the filing, Harrison had served as a member of the Board of Directors since 2021.
  • Filing classification: The disclosure was made under Item 8.01 (Other Events) of the current report.
  • Signed by CEO: The report was signed by David P. Luci, President and Chief Executive Officer, on November 20, 2026.

Acurx Pharmaceuticals Announces Death of Director Thomas Harrison

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) disclosed the unexpected death of board director Thomas Harrison in a current report filed with the SEC on November 20, 2026. The company reported that the event occurred on November 18, 2026, the date of earliest event reported in the filing.

According to the filing, Harrison had been a member of the company's Board of Directors since 2021. The company stated that it "deeply regrets to announce" his passing, characterizing it as unexpected. The disclosure was filed under Item 8.01 (Other Events) of Form 8-K. No additional details regarding board succession or replacement were included in the filing.

The report was submitted on behalf of Acurx Pharmaceuticals by David P. Luci, the company's President and Chief Executive Officer. Acurx Pharmaceuticals is incorporated in Delaware and is classified as an emerging growth company under applicable securities regulations, as indicated on the filing's cover page.

What Was Disclosed

Acurx Pharmaceuticals filed a Form 8-K disclosing the unexpected death of board member Thomas Harrison on November 18, 2026. Harrison had served on the board since 2021. No information regarding board succession was included in the filing.